Weston Medical Publishing LLC Journal of Opioid Management Weston, Massachusetts 02493 781-899-2702



Return To: michael\_glynn@pnpco.com or 781.899.4900 (fax)

DISCLOSURE OF COMMERCIAL RELATIONSHIPS

INTERNATIONAL CONFERENCE ON
<b>OPIOIDS</b>
May 30-June 1, 2020

Activity Title:			Activity Date:	
Name:			Degrees:	
Content Area/Topic:				
☐ Faculty ☐ Course Dire	ector   Author	Reviewer 🗌 Moderato	r 🗌 CNE Cou	rse Advisor   Planning Committee
participate in an accredited active with *commercial interests. The	n all its individually provided vity who is in a position to co intent of this disclosure is to ct can be resolved. <b>Relevant</b>	or jointly provided education ontrol the content is requionaid the CME/CNE Office trelationships identified	itional activities. <i>I</i> ired to disclose ar in determining: 1 on the disclosure	Any individual being considered to my *relevant financial relationships ) if a relevant conflict of interest form, including the absence of such
	( <del>-</del>		_	ng or distributing health care goods or of commercial interest organizations.
ended or is currently active.	ship (any amount) with a conting educational content a	ommercial interest within addressing specific produ	the past 12 mont	h: hs whether the relationship has es of the commercial interest (not
Section 1: Disclosure of Release Regarding your role in this CME commercial interest that is release stockholder, consultant, speaker	activity, have you (or your s ant to or could impact the c 's bureau, employee, other	pouse/partner) had a fina content included in this act	tivity? Relationshi <sub>l</sub>	in the last 12 months with a os include grant/research support,
Recipient: Self or Spouse/Partner	Company	Description o	f Financial	Content Area of Relationship
Example: Self	ABC Company	Grant/Research Supp Consultant, Stockhol		Breast Cancer Research
No disclosure needed for relati	 onships with non-profits or go	vernment units. Add additi	onal lines or sheet i	if necessary
Section 2:				
Have you ever been excluded in federal procurement or no exclusion from such program	on-procurement programs o	or been convicted of a crin	ninal offense that	n federal health care programs or would result in mandatory  NO

I agree to notify Weston Medical Publishing LLC/Internation occurs prior to the completion of the CME Program.	al Conference On Opioids immediately if any of these events
During the last two years, have you violated or received not other continuing education/continuing professional develop	ice of any violations or potential violations related to ACCME/ANCC or ment policies and standards?  YES  NO
	d/investigational use of a commercial product, you are required to her you intend to discuss unlabeled/investigational uses of a commercial
☐ I plan on discussing unlabeled/investigational uses of a	commercial product and will disclose this to the audience.
☐ I do not plan on discussing unlabeled/investigational us	es of a commercial product.
Please list the unlabeled/investigational uses of any product	s that you plan to discuss:
Section 4: Content Validation / Attestation: (This section does not pertain to planners. Planners may pro	ceed to signature section)
<ul> <li>interest, the promotional aspects of that presentation will</li> <li>If I or my spouse/partner is an employee of a commercial of my company. I understand that my presentation must be I understand that a non-conflicted medical reviewer may real will provide educational content and resources in advance.</li> <li>I have reviewed and agree to comply with the ACCME Start CME policies and procedures.</li> <li>All the recommendations involving clinical medicine related profession of medicine as adequate justification for their in All scientific research referred to, reported or used in my conform to the generally accepted standards of experit quality of data provided, I will present the source and type meta-analysis, etc.).</li> <li>Research findings and therapeutic recommendations in minformation and be presented in a balanced, objective mae</li> <li>For any drug/product discussed, I will objectively select an information about the drug/product, and I will include information about the drug/product over another I am discussing specific healthcare products or services, names, I will use trade names from several companies whom I attest to compliance with all applicable laws, including contents.</li> </ul>	or its agent as a speaker (e.g. speaker's bureau) for any commercial not be included in any way with this activity.  Interest, I will not present information on the business lines or products be submitted for review prior to the beginning of the activity.  Interest of review my presentation and/or content prior to the activity, and be as requested.  Indicated for Commercial Support™, Accreditation Criteria, and BUSM  In the indications and contraindications in the care of patients.  Interest of patients of a patient care recommendation mental design, data collection and analysis. To help learners judge the error level of evidence (i.e. animal study, randomized controlled trial, and present data, fairly present both favorable and unfavorable formation about reasonable alternative treatment options. Where there is er, this suggestion will be supported by evidence-based data.  It will use generic names to the extent possible. If I need to use trade an available, and not just trade names from any single company.
Your signature indicates that you have read this form in its	entirety and that you agree with the statements above.
Signature (electronic signatures are acceptable)	Date